A5011312785- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Biochemical and Molecular Research
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Lymphoma Diagnosis and Treatment
- Nuclear Structure and Function
- Ubiquitin and proteasome pathways
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- Cancer Mechanisms and Therapy
- Synthesis of Organic Compounds
- PI3K/AKT/mTOR signaling in cancer
- Cancer Cells and Metastasis
- Neuroblastoma Research and Treatments
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Glioma Diagnosis and Treatment
Wayne State University
2015-2024
The Barbara Ann Karmanos Cancer Institute
2013-2024
Hamad Medical Corporation
2012-2019
ProNAi Therapeutics (United States)
2007
Palmetto Hematology Oncology
2005
New York Proton Center
1997
Kettering University
1997
Memorial Sloan Kettering Cancer Center
1997
Cancer Research Institute
1993
Harper University Hospital
1993
CD437, a novel retinoid, causes cell cycle arrest and apoptosis in number of cancer cells including human breast carcinoma (HBC) by utilizing an undefined retinoic acid receptor/retinoid X receptor-independent mechanism. To delineate mediators CD437 signaling, we utilized random antisense-dependent functional knockout genetic approach. We identified cDNA that encodes ∼130-kDa HBC perinuclear protein (termed CARP-1). Treatments with or chemotherapeutic agent adriamycin, as well serum...
Abstract Overexpression of Bcl-2 family proteins has been found in a variety aggressive human carcinomas, including pancreatic cancer, suggesting that specific agents targeting would be valuable for cancer therapy. We have previously reported TW-37, small-molecule inhibitor proteins, inhibited cell growth and induced apoptosis cancer. However, the precise role molecular mechanism action TW-37 not fully elucidated. In our current study, we induces inhibition S-phase cycle arrest, with...
MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It closely related MDM2 antagonists MI-219 and Nutlin-3 in terms of expected working mechanisms. The purpose this study was evaluate anti-lymphoma activity WSU-FSCCL, B-cell follicular lymphoma line. For comparison purpose, MI-319, were assessed side by against FSCCL three other hematological tumor cell lines growth inhibition gene expression profiling experiments. shown bind protein with an affinity slightly...
Summary. Trans ‐resveratrol was analysed for its apoptotic and growth inhibitory activity in human B‐cell lines derived from chronic malignancies (WSU‐CLL ESKOL), leukaemic lymphocytes patients with lymphocytic leukaemia (B‐CLL). Resveratrol displayed antiproliferative on both lines, as estimated by the decrease cell recovery inhibition of thymidine uptake. Furthermore, resveratrol induced apoptosis two well B‐CLL patients' cells, evidenced increase annexin V binding, caspase activation, DNA...
Asfar S. Azmi 1 , Sanjeev Banerjee Shadan Ali Zhiwei Wang Bin Bao Frances W.J. Beck 2 Main Maitah Minsig Choi Tony F. Shields Philip A. Fazlul H. Sarkar Ramzi M. Mohammad Department of Pathology, Wayne State University School Medicine Departments Oncology, Karmanos Cancer Institute, Medicine, Detroit, Michigan Keywords: MDM2 and p53, MI-219, oxaliplatin Network Modeling Received: April 28, 2011; Accepted: May 11, Published: 16, Correspondence: H Sarkar, e-mail: // Mohammad, Abstract Earlier...
Background Pancreatic cancer is a highly malignant disease with an extremely poor prognosis. Histone deacetylase inhibitors (HDACIs) have shown promising antitumor activities against preclinical models of pancreatic cancer, either alone or in combination chemotherapeutic agents. In this study, we sought to identify clinically relevant histone deacetylases (HDACs) guide the selection HDAC tailored treatment cancer. Methodology expression seven cell lines and normal human ductal epithelial...
The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door targeting selectively. These agents have shown promise preclinical tumor models clinical trials. FDA recently granted approval sotorasib for mutated non-small cell lung cancer (NSCLC). However, patients receiving these as monotherapy generally develop drug resistance over time. This necessitates development multi-targeted approaches potentially sensitize...
Despite the exceedingly poor prognosis of pancreatic cancer, it is often histologically well to moderately differentiated. The apparent resistance conventional therapeutic modalities poorly understood and may be related molecules involved in its progression or propensity for perineurial invasion. Cyclooxygenase-2 (COX-2) an inducible enzyme homologous COX-1 that responsible production prostaglandins at sites inflammation. It activated by a variety growth factors tumor promoters, has been...
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in United States, suggesting that novel strategies for prevention and treatment PDAC are urgently needed. K-ras mutations observed >90% pancreatic cancer, its role initiation early developmental stages PDAC. In order to gain mechanistic insight as mutated K-ras, several mouse models have been developed by targeting a conditionally K-ras(G12D) recapitulating A significant co-operativity has shown tumor...
Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public spaces. We previously identified 1,5-anhydro-D-glucitol (1,5-AG) saliva as a biomarker. The Glycomark™ assay kit is FDA approved for 1,5-AG measurement blood. Here we evaluated its applicability quantification saliva.Using pooled samples, validated use with RX Daytona(+) clinical chemistry analyser. then used this set-up to analyse 82 paired samples from case-control study, which broad...
Abstract Background Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting HDM2-p53 interaction by small-molecule inhibitors (SMIs). HDM2 have been developed and are under various stages preclinical clinical investigation. Previously, we examined anti-lymphoma activity MI-319, laboratory grade new class SMI, spiro-oxindole, in follicular lymphoma....
Oxaliplatin has been a crucial component of combination therapies since admission into the clinic causing modest gains in survival across multiple malignancies. However, oxaliplatin functions non-targeted manner, posing difficulty ascertaining precise efficacy mechanisms. While previously thought to only affect DNA repair mechanisms, Platinum-protein adducts (Pt-Protein) far outnumber Pt-DNA leaving big part function unknown. Through preliminary network modeling high throughput data, this...
Abstract The erbB family of receptor tyrosine kinases plays critical roles in human cancers, including pancreatic cancer. Discovering a specific agent, which targets multiple members the family, would be important cancer therapy. Recently, we isolated novel negative regulator epidermal growth factor (EGFR), termed EGFR-related protein (ERRP), whose expression attenuates EGFR activation. In current study, examined effects recombinant ERRP on and ligand-induced activation three cell lines that...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority patients with PDAC have mutations KRAS, which unfortunately remains an ineffectual target. Our strategy here to target KRAS downstream effectors PI3K and mTOR. In this study, we investigated the antitumor efficacy novel mTOR dual inhibitor VS-5584 PDAC. data shows that PI3K/mTOR inhibition causes ERK activation all tested cell lines. Although MEK GSK1120212 could abrogate...